Insurance Medicine

In this, the last of our 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of how genomic sequencing of cancers is blasting a trail for improved, early diagnosis and precision medicine by providing a powerful and ever-expanding means to detect, identify, subdivide and monitor cancer – and how this remarkable development could impact Life & Health insurers.

This article is the last in a three-part series, highlighting areas of research funded by the Longer Life Foundation (LLF), a not-for-profit organization that supports the study of scientific and public health factors predicting mortality, morbidity, longevity, and wellness.
 

Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of targeted cancer therapy – a catch-all term for a spectrum of innovative new cancer therapies that are improving the outlook for patients and moving us closer to precision medicine – and its impact on Life & Health insurers.
 

Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of liquid biopsy, one of the most exciting potential advances in cancer research. With promising results to-date for certain late-stage cancers, early and painless diagnosis from liquid biopsies could have huge positive consequences for wider cancer treatments and recoveries.
 

In this, the first of a 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, focuses on how these advances translate into high-level trends, and why they are so important to Life & Health insurance – all in a concise bulleted format, so there’s no need to wade through complex medical descriptions or interpret sensationalized headlines.
 

RGA's Dr. Maryam B. Shapland, Vice President and Medical Director, U.S. Mortality Markets, explores reactive thrombocytosis, a condition associated with higher mortality in acutely ill patients.
 

In this edition of ReCent Medical News, Dr. Cliff Titcomb explains asthma characteristics and possible challenges for medical underwriters.
 

Smokeless tobacco has been evolving over the past 55 years and now, with various forms of e-cigarettes and additives available, this once ‘safer’ recreational activity is showing implications on brain, lung, and cardiovascular function. 
 

Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
 

Hypertension, or high blood pressure, is a common medical problem. It can be caused by a number of other medical conditions such as chronic kidney disease, thyroid disorders and other hormonal upsets, and a rare adrenal gland tumor called pheochromocytoma.